Trial
NCT01175330
Omega 3 Fatty Acid Efficiency for Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Meshalkin Research Institute of Pathology of Circulation
Collaborators
—
Condition
Ischemic Heart Disease
Intervention
Omega-3 fish oil emulsion (Omegaven)
Why stopped
Interim analysis did not reveal of anticipated benefits of intervention
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-03-24